What We're Reading: Page 144
Industry reads hand-picked by our editors
Oct 13, 2021
-
The Financial Times
Covid success of mRNA vaccines opens way to a new generation of drugs
-
Bloomberg
Bristol-Myers Is Said to Have Weighed Offer for Acceleron
-
Reuters
Lonza shores up investment budget to capitalise on biotech boom
-
Endpoints News
As TRIPS council meets, the IP waiver for vaccines is on life support ahead of a December deadline
Oct 12, 2021
-
The Wall Street Journal
Johnson & Johnson’s Top Scientist to Depart
-
Chemical & Engineering News
Preventive cancer vaccine based on neoantigens gets put to the test
-
Evaluate Vantage
Triple meeting – low-profile assets boost Merus and Bicycle
-
The Financial Times
Covid response hampered by population data glitches
Oct 11, 2021
Oct 08, 2021
Oct 07, 2021
-
The New York Times
First Malaria Vaccine Approved by W.H.O.
-
STAT
Amgen's Lumakras disappoints in combination with other drugs
-
Roll Call
FDA’s internal turmoil could impact boosters, shots for kids
-
MIT Technology Review
Tech millionaire Steve Kirsch went from covid trial funder to misinformation superspreader
Oct 06, 2021
Oct 05, 2021
-
Associated Press
Henrietta Lacks estate sues company using her 'stolen' cells
-
ProPublica
McKinsey Never Told the FDA It Was Working for Opioid Makers While Also Working for the Agency
-
Reuters
A year after COVID vaccine waiver proposal, WTO talks are deadlocked
-
C&EN
Exo Therapeutics raises $78 million to target enzyme exosites with small molecules
Previous
